Back to News
Market Impact: 0.35
Novo Will Work With Anthropic AI to Speed Drug Development
Source: Bloomberg
Artificial IntelligenceHealthcare & BiotechTechnology & InnovationCorporate Guidance & Outlook
Novo Nordisk and Anthropic will collaborate to accelerate drug development using artificial intelligence. The partnership supports Novo's effort to improve innovation speed and competitiveness in the highly competitive obesity-treatment market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVO0.35
More News
- H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end
- 'Hostile act': Trump threatens EU with tariffs over Canada associate-membership proposal
- US official says upcoming spectrum auctions could generate more than $100 billion
- 'Science fiction': Transport companies — the backbone of economy — are sounding alarm on fuel prices
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- Fed delivers its first hike in 3 years. Plus, what's moving Starbucks and GE Vernova